Earnings Feed
Start Free
Edwards Lifesciences Corp·4

May 8, 9:16 PM ET

Chopra Daveen 4

Research Summary

AI-generated summary

Updated

Edwards Lifesciences CVP Daveen Chopra Receives Stock Awards

What Happened
Daveen Chopra, CVP, TMTT & Surgical at Edwards Lifesciences (EW), received equity awards on May 7, 2026 and had shares withheld to cover tax liabilities. The filing shows:

  • Time-based restricted stock units (RSUs): 9,675 shares granted (acquired at $0.00).
  • Stock options: 49,100 granted (derivative award, $0.00 acquisition reported).
  • Performance RSU target award: 9,675 target shares granted (derivative; actual vesting 0–200% based on performance).
    To cover tax withholding/related payments, Chopra had 674 shares disposed on 2026-05-07 at $83.20 each ($56,077) and 1,141 shares disposed on 2026-05-08 at $82.76 each ($94,429), totaling 1,815 shares and $150,506.

Key Details

  • Transaction dates & prices:
    • Grants dated May 7, 2026: 9,675 RSUs; 49,100 options; 9,675 performance-target RSUs (reported at $0.00 acquisition price).
    • Tax-withholding disposals: May 7, 2026 — 674 shares @ $83.20 ($56,077); May 8, 2026 — 1,141 shares @ $82.76 ($94,429).
  • Shares withheld/sold for taxes: 1,815 shares; total proceeds used for tax/payment = $150,506.
  • Shares owned after transaction: Not specified in this Form 4 (the filing notes it reflects changes only).
  • Vesting/vesting terms (footnotes):
    • Time-based RSUs and options vest in four equal annual installments beginning one year after grant.
    • Performance RSUs vest May 7, 2029 subject to 0–200% payout based on a three-year performance period.
  • Filing timeliness: Form 4 filed May 8, 2026 (covers activity on May 7–8); no late filing flag noted.

Context

  • These were compensation awards (RSUs, options, performance RSUs), not open-market purchases — awards reflect company compensation, not necessarily a direct bullish signal.
  • The disposals were tax-withholding/cashless-type actions (code F), common when RSUs vest or awards are granted; they do not necessarily reflect a voluntary sale for investment reasons.
  • Options and time-based RSUs require future vesting before Chopra can sell underlying shares; performance RSU payout depends on achieving targets through 2029.